TAK-285 is a novel dual HER2 and EGFR inhibitor with IC50 of 17 nM and 23 nM, respectively. A Phase I study of TAK-285 in patients with advanced cancer has been completed. TAK-285 is a novel, orally active, dual HER2/EGFR inhibitor with antitumor activity in mouse xenograft models, including breast, gastric, lung, and colon cancer.